FIELD OF THE INVENTION
The present invention relates to peptides for treating lung injury, including inflammation-mediated vascular leakage and the development of edema. The present invention also relates to treating asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and
FIELD OF THE INVENTION
The present invention relates to peptides for treating lung injury, including inflammation-mediated vascular leakage and the development of edema. The present invention also relates to treating asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and
BACKGROUND OF THE INVENTION
Platelet-activating factor (PAF) has recently been identified as an acetyl glyceryl ether phosphorylcholine (AGEPC), i.e., 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (Hanahan D. J. et al., J. Biol. Chem. 255:5514, 1980). Even before its chemical
BACKGROUND OF THE INVENTION
Platelet-activating factor (PAF) has recently been identified as an acetyl glyceryl ether phosphorylcholine (AGEPC), i.e., 1-0-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorycholine (Hanahan D. J., et al., J. Biol. Chem. 255:5514, 1980). Even before its chemical
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter
The present invention relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof.
More particularly, it relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof, which are adenosine antagonists and possess various pharmaceutical actions
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein
R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl,
R.sub.b
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size.
FIELD OF THE
FIELD OF THE INVENTION
The invention relates to compositions and methods of use of anti-histone antibodies or antigen-binding fragments thereof. In particular embodiments, the antibodies bind to human histones H2B, H3 or H4. The anti-histone antibodies are of use for diagnosis and/or therapy of a
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size.
FIELD OF THE
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size.
FIELD OF THE
Najkompletnija baza ljekovitog bilja potpomognuta naukom
Radi na 55 jezika
Biljni lijekovi potpomognuti naukom
Prepoznavanje biljaka po slici
Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
Pročitajte naučne publikacije povezane sa vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi. * Sve informacije temelje se na objavljenim naučnim istraživanjima